CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor, Breast Cancer

In brief

The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.

Key facts

Study ID

NCT05251714

Run by

Treadwell Therapeutics, Inc

People needed

44

Starts

2022-05-27

Expected to finish

2026-08-01

Last updated by the study team

2025-05-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• START San Antonio — San Antonio, Texas, United States
• START - Mountain Region — West Valley City, Utah, United States
• Virginia Cancer Specialist — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.